Senate Bill Expands FDA's OTC Manufacturing Oversight
This article was originally published in The Tan Sheet
Legislation introduced in the Senate to give FDA mandatory recall authority for all drugs would bar the agency from considering a drug's prescription status when assessing risk to prioritize inspections
You may also be interested in...
Harkin Eyes Inspection Fees For Drug, Ingredient Manufacturers
Sen. Tom Harkin is considering a fee on drug firms to pay for facility inspections.
Monograph Modernization Initiative Looks To Close OTC Quality Loopholes
A collaboration among industry, FDA and U.S. Pharmacopeia aims to address what FDA sees as a lack of insight into the quality and purity of OTC monograph drugs
J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.